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Available online 10 May 2011Abstract Cell therapy has the potential to offer novel treatment modalities for a number of diseases including cancer, and
stem cells and in particular mesenchymal stem cells (MSCs) have been experimentally used to deliver therapeutic transgenes.
However, conflicting reports have on the one side found that human MSCs can promote metastasis, while on the other
hand other studies have shown that MSCs can stall the growth of metastatic lesions. In order to clarify the role of MSCs in
metastasis development, we tested whether murine MSCs would behave similarly to human cells in mice. We found that the
tissue distribution of human and mouse MSCs was nearly identical after intravenous injection. In mice with MDA-MB-231
mammary carcinoma xenografts we found that a fraction of MSCs infiltrated the primary tumor mass, but that the general
tissue distribution of MSCs was unaffected by the tumor-burden. About half of the tumor-burdened animals that were treated
with murine and human MSCs, respectively, harbored metastatic lesions with only 17% of controls showing metastatic nodules.
Hence, both human and mouse MSCs possess metastasis-promoting activity raising concerns about the safe use of MSCs,
but at the same time making the use of murine transgenic model systems feasible to study the role of MSCs in metastasis
development and possibly finding ways of using them safely as cell therapeutic vehicles.
© 2011 Elsevier B.V. All rights reserved.Introduction
Metastasis is the most frequent and life-threatening com-
plication associated with cancer. It is estimated that more
than 90% of deaths in cancer patients are due to the direct
or indirect effects of metastasis (Sleeman and Steeg, 2010).
Despite of substantial advances in our knowledge regarding
tumor treatments, the attempts to cure advanced cancer
patients are still hampered by the extent and heteroge-
neity of the tumor burden, the acquisition of multiple drug⁎ Corresponding author at: National University of Ireland, Galway,
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doi:10.1016/j.scr.2011.05.002resistance and survival mechanisms in the diverse popula-
tion of cells that comprise advanced metastatic lesions
(Sporn, 1996). Thus, novel treatment approaches are urgent-
ly needed.
Cell therapy is an emerging medical field that opened the
possibility for the treatment of a wide range of pathologies
including cancer. In recent years several research groups
have reported on the successful use of unaltered or engineered
MSCs for the treatment of tumors including metastatic lesions
in various model systems (Studeny et al., 2002; Mohr et al.,
2010). MSCs are stromal cells that normally reside within
the adult bonemarrow and are able to differentiate intomany
adult cell types such as osteocytes, chondrocytes and adi-
pocytes (Barry and Murphy, 2004; Dominici et al., 2006). Re-
cent studies have shown their ability to migrate and home
to injured and tumor sites and their utility as anti-tumor cell
and gene therapy vehicle is based on these characteristics.
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et al., 2006; Hall et al., 2007). This means that systemically
administered MSCs following transduction with non-viral or
viral vectors that contain specific tumoricidal transgenes
can seek out sites of malignant growth and deliver their
therapeutic payload (Baksh et al., 2004; Motaln et al., 2010).
However, the last few years have also witnessed a growing
controversy about the effects of MSCs on tumor cells with
some publications reporting a metastasis-promoting activity
(Karnoub et al., 2007; Molloy et al., 2009), whereas others
showed inhibition of tumor cell growth and dissemination
by MSCs (Khakoo et al., 2006; Sun et al., 2009).
It is noteworthy that these studies used human MSCs in
murine models for human cancers and we wondered wheth-
er possible unphysiological, non-specific functions of human
cells in a murine context could be the cause of the observed
effects of MSCs on tumor cells. Therefore, we compared the
homing potential of murine and human MSCs after systemic
administration and their potential capacity for metastasis
induction in various cancer models.Results
Tissue distribution of murine and human MSCs
MSCs derived from bone marrow have the potential to dif-
ferentiate in vitro along numerous mesenchymal lineages
(Mackay et al., 1998; Wakitani et al., 1994; Majumdar et al.,
1998). Only the induction of differentiation in vitro provides
a test system to validate a specific MSC preparation for its
pluripotency. We carried out differentiation to adipocytes,
osteoblasts and chondrocytes on our murine (Supplementary
Fig. 1A) and human MSCs (Supplementary Fig. 1B). After
having established the stemness of our murine and human
MSCs we went on to examine their tissue distribution follow-
ing systemic administration and their potential to promote
metastasis.
In order to test the tissue tropism of MSCs, we intrave-
nously injected 1×105 CM-Dil labeled mouse and human
MSCs, respectively, into nu/numice. Oneweek post-injections
we analyzed micro-sections from bone marrow, liver, lymph
nodes, lung and spleen for the presence of MSCs (Fig. 1A,
Supplementary Figs. 2A, B and for larger images of the
magnified areas Supplementary Figs. 7A, B). Our quantita-
tive analysis on sections of these tissues showed that more
than 43–44% of both murine and human MSCs had infiltrated
lymph nodes, 36% the spleen and 8–12% bone marrow and
liver, whereas only 1–3% were detected in the lungs
(Fig. 1B). Other tissues such as brain, heart, and kidney
were virtually free of MSCs (data not shown). This means
that there was no overall difference in the relative bio-
distribution pattern between murine and human MSCs. In
order to provide the cell numbers, on which the relative bio-
distribution analysis (Fig. 1B) is based, we show the same
profile using numbers of total detected MSCs in the five
tissues (Fig. 1C). Furthermore, we analyzed the number of
MSCs in relation to the total number of cells on sections from
each of the tissues revealing that the density of MSCs is
highest in liver, lymph nodes and spleen (Fig. 1D). These
findings demonstrate that systemically injected MSCs from
the two species behave similarly in a nu/nu mouse model.Previous studies that had used different methods to de-
tect MSCs (bioluminescent imaging and real-time PCR, re-
spectively) and had analyzed MSC bio-distribution over a
wider time course including very short-time points follow-
ing the administration of MSCs (Kidd et al., 2009; Lee et al.,
2009) had shown a pronounced accumulation of MSCs in the
lungs on day 1 that started to disappear 5 days after the
injection of MSCs. At this time point the cells started to be
detectable in liver and spleen in increasing numbers, sim-
ilar to our results. In order to validate our results and ren-
der them comparable to the before mentioned studies we
conducted an experiment including a short time point. To
this end, we examined the numbers of Dil-labeled human
MSCs in the lung 15 min after injection and compared it to
the values after 1 week (Supplementary Figs. 3A, B, C). We
found a 6.5-fold reduction of the MSC numbers in the lungs
over this time frame, which is broadly in line with the pre-
vious reports.
Tissue distribution of murine MSCs in syngenic,
immune-competent mice
In order to evaluate the tissue distribution of MSCs in a fully
syngenic model, we used murine FVB-derived MSCs in FVB/N
mice. We intravenously injected 1×105 CM-Dil labeled
mouse MSCs and analyzed bone marrow, liver, lymph
nodes, lung and spleen for the presence of MSCs 1 week
after the injections (Fig. 2A and for larger images of the
magnified areas Supplementary Fig. 8). The quantitative
analysis showed a three fold drop in detected MSCs as
compared to immune-deficient mice, but an almost equiv-
alent presence of MSCs in bone marrow, liver and lymph
nodes, with 25% of all detected MSCs in each of the three
tissues. The remaining cells were found with 9% in the lungs
and 17% in the spleen (Figs. 2B, C). In comparison to nu/nu
mice we found relatively small differences in the tissue
distribution pattern of MSCs in this syngenic model. The
most striking differences were that relatively more cells
homed to the bone marrow and the liver. This led to a higher
cellular density of MSCs in the liver and fewer MSCs in lymph
nodes and spleen in relation to the total number of cells on
the analyzed tissue sections (Fig. 2D). However, the overall
trend of infiltration of substantial numbers of MSCs in
lymphatic tissue, liver, spleen and bone marrow on the one
side and substantial smaller numbers in the lungs at this time
point remained the same. These findings demonstrate that
the bio-distribution of systemically injected MSCs is broadly
similar in immune-deficient and immune-competent mice.
Tissue distribution of MSCs over time and
in tumor-burdened animals
Next, we investigated whether the tissue distribution of
MSCs might change over time and whether differences be-
tween murine and human cells might become apparent at
this later time point post-injection. Our results show that
after 4 weeks the relative tissue distribution pattern of
the MSCs was overall unchanged (Fig. 3A) as compared to
the one-week time point. Again, MSCs did not appear in
the other organs (brain, heart, kidney) in any substantial
numbers (data not shown).
Figure 1 Tissue distribution of murine and human MSCs. (A): CM-Dil labeled murine (left panels) and human MSCs (right panels) are present in bone marrow (BM), liver, lymph nodes
(LN), lung and spleen. The MSCs are indicated by red arrows. The tissues were counterstained with DAPI. The DAPI stains are depicted in the first column of images, the CM-Dil label in
the second column, the superimposed images of DAPI and CM-Dil in the third column and images of magnified areas, which are indicated by a white-lined box, in the fourth column.
Shown are representative images. (B): Quantification of the relative tissue distribution of murine (green bars) and human (red bars) MSCs 1 week after intravenous injection. (C):
Quantification of the total number of murine (green bars) and human (red bars) MSCs in the analyzed microsections from the respective tissues 1 week after intravenous injection. (D):
Depicted are the number of murine (green bars) and human (red bars) MSCs in relation to the total number of cells in the analyzed sections. For the analyses, a total of 15 randomly


















Figure 2 Bio-distribution of murine MSCs (derived from FVB/N mice) in immune-competent FVB/N mice. (A): CM-Dil labeled murine
MSCs are present in bone marrow (BM), liver, lymph nodes (LN), lung and spleen. The MSCs are indicated by red arrows. The tissues were
counterstained with DAPI. The DAPI stains are depicted in the first column of images, the CM-Dil label in the second column, the
superimposed images of DAPI and CM-Dil in the third column and images of magnified areas, which are indicated by a white-lined box, in
the fourth column. Shown are representative images. (B): Quantification of the relative tissue distribution of murine MSCs 1 week after
intravenous injection. (C): Quantification of the total number of murine MSCs in the analyzed microsections from the respective tissues
1 week after intravenous injection. (D): Depicted are the numbers of murine MSCs in relation of the total number of cells in the analyzed
sections. For the analyses, a total of 15 randomly chosen fields were counted for each tissue. Three animals were analyzed.
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distribution analysis (Fig. 3A) is based, we show that the
profile was not markedly altered when using numbers of
total detected MSCs in the five tissues in comparison to the
results of one week post-injections (Fig. 3B). Similarly, the
cellular density of MSCs in the different tissues was also
broadly unchanged (Fig. 3C). We then hypothesized that
the presence of tumor cells might influence the behavior
of MSCs and that a species specific difference might be-
come apparent then. However, when we had established
MDA-MB-231 human breast cancer xenografts in nu/nu mice
before we injected 1×105 CM-Dil labeled MSCs we observed
no substantial differences in the tissue distribution pro-
file of murine and human MSCs in tumor-burdened animals
(Figs. 3D, E). We did, however, notice, a rise in the number
of MSCs in tumor-burdened animals (Fig. 3E) also resulting
in a higher proportion of MSCs in relation to the total num-
ber of cells in the analyzed organs (Fig. 3F). Interestingly,
the tumor-induced increase in MSC numbers was more pro-
nounced with murine MSCs as compared to human MSCs.Hence, significantly more murine MSCs than human MSCs
were found in the tumor burdened animals, in particular in
spleen, lymph nodes and lungs, as murine MSCs either pro-
liferated more profoundly, were better protected from
cell death or were retained more effectively in the tissues.
In a subsequent, separate experiment we included the pri-
mary xenografts in our analyses and showed that a proportion
of the injectedMSCs had homed to the tumors (Supplementary
Fig. 4A). Quantification of the bio-distribution of murine and
human MSCs in this experiment showed that between 2%–5%
of the cells were found in the tumor masses (Supplementary
Fig. 4B). The numbers of MSCs in tumor tissue sections were
relatively low (Supplementary Fig. 4C) but contributed to
cellular density of the tumor almost to the same degree as
in bone marrow and lymph nodes (Supplementary Fig. 4D).
The distribution pattern in the other tissues was compara-
ble to the results shown in Figs. 3D–F with the values only
reduced by the small fraction of the tumor-infiltrating MSCs
(Supplementary Figs. 4B, C, D). Again, we found signifi-
cantly more murine MSCs than human MSCs in particular in
Figure 3 The tissue distribution profile of MSCs does not change over time and in tumor burdened animals. (A): Quantification of the
relative distribution of murine (green bars) and human (red bars) MSCs 4 weeks after intravenous injection. (B): Quantification of the
total number of murine (green bars) and human (red bars) MSCs in the analyzed microsections from the respective tissues 4 weeks
after intravenous injection. (C): Depicted are the number of murine (green bars) and human (red bars) MSCs in relation to the total
number of cells in the analyzed sections 4 weeks after intravenous injection. (D): Quantification of the relative distribution of murine
(green bars) and human (red bars) MSCs 4 weeks after intravenous injection into tumor burdened animals. (E): Quantification of the
total number of murine (green bars) and human (red bars) MSCs in the analyzed microsections from the respective tissues 4 weeks
after intravenous injection into tumor burdened animals. (F): Depicted are the number of murine (green bars) and human (red bars)
MSCs in relation to the total number of cells in the analyzed sections of tumor-burdened animals. For the analyses, a total of 15
randomly chosen fields were counted for each tissue. For the non-tumor burdened analyses three animals per group and for the tumor-
burdened analyses seven animals per group were analyzed.
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nodes. There was no significant difference between murine
MSCs and human MSCs in the primary tumor tissue. These
findings demonstrate that the established tumors did impact
on the total numbers of MSCs, but did not affect the general
tropism of both, murine and human MSCs, and their bio-
distribution profile.Both human and murine MSCs promote metastasis
Finally, we examined the impact of MSCs on metastatic
behavior of cancer cells. First, we used MDA-MB-231 human
breast cancer cells. After having established MDA-MB-231
human breast cancer xenografts in nu/nu mice for 3 weeks,
we injected 1×105 CM-Dil labeled murine or human MSCs
into the tail vein. Four weeks after the injection of MSCs we
examined bone marrow, liver, lymphnodes, lung and spleen
from these animals for metastasis formation on H&E stained
sections of these tissues (Fig. 4A). We found that 54% and 42%
of all animals that were treated with murine and human
MSCs, respectively, had metastatic growths in their lungs andin some rare cases in the liver (Fig. 4B). In control animals
that were not injected with MSCs we could detect metastatic
nodules in the lung in only 17% of the mice and none in the
liver (Fig. 4B). Furthermore, in animals that received murine
or human MSCs but no tumor cells we could not detect lesions
in lungs or liver ruling out that MSCs form neoplastic nodules
in our experimental model (Fig. 4B).
When we compared the extent of metastatic growth in
animals that receivedmurine MSCs to those that received cells
of human origin, we found that the former exhibited more
aggressively growing tumor nodules in the lung (Fig. 4C). In
order to confirm that the lesions did indeed originate from
humanMDA-MB-231mammary carcinoma cells we stained lung
microsections from tumor-burdened mice that were injected
with murine MSCs with an antibody specific to human CD326.
The antibody detected human CD326 on the surface of
cells in tumor nodules in the lung (Supplementary Fig. 5A),
whereas lungs from non-tumor burdened animals that had
been injected with murine MSCs exhibited no lesions in their
lungs (Supplementary Fig. 5B) and were negative for human
CD326 (Supplementary Fig. 5C). Furthermore, in an immuno-
cytochemical study the CD326 antibody only emits a signal
Figure 4 Both human and murine MSCs can promote metastasis (A): Analysis of lung metastasis in MDA-MB-231 tumor-burdened
animals that received no MSCs (left), human MSCs (hMSC; center) or murine MSC (mMSC; right). Tumor tissue is marked by a white T.
Shown are representative images of H&E stained microsections of lung tissues. The images show that both human and murine MSCs
promote metastasis but the latter give rise to more aggressively growing tumor nodules. (B): Quantification of the occurrence of lung
(upper table) and liver (middle table) metastatic lesions in MDA-MB-231 tumor-burdened mice that received no MSCs, human MSCs or
murine MSC as well as control mice (lower table) that only received murine MSCs and human MSCs, respectively. Shown are the number
of animals with metastasis and the total number of animals analyzed from each group (number in parenthesis) as well as the
percentages of affected animals. (C): Quantification of the number of metastatic nodules in MDA-MB-231 tumor-burdened mice that
received human MSCs (red bar) or murine MSC (green bar) demonstrating that murine MSCs possess a higher pro-metastatic activity
than human MSCs in our model system. For these analyses, 20 randomly chosen low-power fields from human lung sections and 24
murine lung sections were counted.
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and mouse MSCs further demonstrating the specificity of the
antibody (Supplementary Fig. 5D). Moreover, when we exam-
ined lung tumor lesions from tumor-burdened mice that were
injected with CM-Dil labeled murine MSCs we could detect
single MSCs inside as well as outside of the lesions, but in no
case was the nodule made up entirely or in its majority from
red-fluorescing MSCs (Supplementary Fig. 5E). Hence, while
we cannot completely rule out that (transformed) MSCs
also form metastasis-like nodules, our results show that the
lesions we detected, at least in the majority, stemmed from
human breast cancer cells. These findings demonstrate that
murine as well as human MSCs can promote metastasis for-
mation of mammary carcinoma cells.
In addition, we tested the metastasis-promoting poten-
cy of MSCs in two additional tumor models, the 4T1 breast
cancer and the HCT116 colorectal cancer model. 4T1 cells
are highly metastatic, murine breast cancer cells and have
been extensively used to study the tumor dissemination
process. We subcutaneously injected 5×106 of 4T1 cells into
the flank of BALB/c mice and waited until the primary tumor
was palpable, usually after 1 week. Then, we intravenously
injected 1×105 MSCs into the tumor-burdened mice. After
3 weeks we examined the lungs of these animals for metas-
tases and found that all mice regardless of whether they hadreceived MSCs or not had developed cancerous growth in their
lungs (Supplementary Figs. 6A, B). Quantification of the met-
astatic burden, both on a macroscopic and microscopic level,
also revealed no significant differences between the cohorts
(Supplementary Fig. 6C). Hence, 4T1 cells possess metastatic
properties that cannot be further enhanced by the action of
MSCs. Therefore, we turned to a third tumor cell type, namely
HCT116 cells that normally do not disseminate when grown
as subcutaneous xenografts. In this model no lung metas-
tases formed in control animals (no MSCs), but in animals
injected with MSCs we found metastatic lesions in 3 out of 5
mice (Supplementary Figs. 6D, E, F). In summary, MSCs exert
pro-metastatic effects on low to medium invasive tumor cells,
but seem to fail to further aggravate the metastatic potential
of highly aggressive cancers.Discussion
MSCs have been proposed as cellular tumor therapy vehicle,
either utilizing their proposed intrinsic anti-cancer proper-
ties or in combination with the expression of therapeutic
transgenes. Furthermore, MSCs have been used and even
tested in clinical trials for a variety of degenerative disorders
and as immune-suppressors in for example Graft-versus-host
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of MSCs appears plentiful (Motaln et al., 2010; Baksh et al.,
2004), Karnoub et al. (Karnoub et al., 2007) have reported
that human MSCs promote the development of metastasis in
a human breast cancer model. These results raise serious
concerns regarding the safe use of MSCs in cell therapeutic
applications in general and tumor treatments in particular.
We asked whether the use of human MSCs in those studies
might have led to unspecific effects owing to a non-
physiological tropism of the human cells in a mouse organism.
Therefore, we examined and quantified the locations of
systemically administered human MSCs and compared them
to their murine counterparts. We found no difference with
regard to the total number of cells as well as relative tissue
distribution between MSCs from the two species, which also
did not change over time. Furthermore, we askedwhether the
presenceof a tumor could influence the homing characteristics
of MSCs.While we detected an overall increase in the numbers
of MSCs, in particular of murine MSCs, in tumor-burdened
animals, we found no differences between murine and human
MSCs in the overall tissue distribution profile as well as no
changes compared to non-tumor burdened animals. Hence, it
appeared unlikely that the metastasis promoting activity of
human MSC was caused by an unusual tissue distribution.
Finally, we examined the impact of systemically administered
MSCs on the capacity of human mammary carcinoma cells to
metastasize and found that both murine and human cells
promoted the formation of metastatic lesions in the lungs.
Further analysis revealed thatmurineMSCs causedmore highly
aggressive lesions compared to human MSCs. These findings
argue for an evolutionary conserved signal or signals that
mediate the pro-metastatic activity of MSCs and highlight the
feasibility of transgenic murine model systems to study the
role of MSCs in metastasis development, thereby providing a
potential valuable research tool for elucidation of the cellular
and molecular mechanisms during tumor dissemination. When
we used two other human cancer models, a highly metastatic
mammary cancer cell line, 4T1, and a non-metastatic human
colorectal cancer cell line, HCT116, we found that MSCs did
not significantly promote dissemination of 4T1 tumors,
whereas metastasis development was dramatically increased
in the HCT116 model. These results indicate that highly
malignant cancer cells possess sufficient intrinsic metastatic
potential that cannot be further enhanced by signals emitted
by MSCs, whereas tumor cells with little metastatic activity
appear to receive cues from MSCs that increase their
dissemination to distal organs. The chemokine CCL5 (also
known as RANTES) secreted from MSCs and its cognate
receptor CCR5 expressed on the surface of cancer cells have
been implicated in this process (Karnoub et al., 2007).
However, while the CCL5-CCR5 axis appeared to be responsi-
ble for the pro-metastatic function of MSCs in MDA-MB-231 and
MDA-MB-435 breast carcinoma cells, it had no effect in a
number of other mammary cancer cells, pointing to the
existence of additional or alternative signals.
Moreover, we cannot completely rule out that MSCs in
the lungs, where they home to in large numbers immediately
after injection, create a pre-metastatic niche for tumor me-
tastasis to develop later. However, the findings by Karnoub
et al.(2007) and the time gap between MSC-infiltration and
appearance of metastatic lesions in the lungs make this
explanation less likely. Irrespective of the two possible mech-anisms, i.e. interaction betweenmesenchymal cells and tumor
cells vs. creation of a pre-metastatic niche, the analysis and
elucidation of the underlying molecular factors and pathways
might provide new ways to prevent and/or treat metastatic
disease.
For MSCs as a cellular therapeutic it means that the factors
that afford their pro-metastatic activity have to be fully iden-
tified and then eliminated so that they can be used safely.Material and methods
Reagents
All chemicals, reagents and media, unless otherwise stated,
were purchased from Sigma. TGF-β was purchased from
Peprotech.Cell culture
The breast cancer cell line MDA-MB-231 was cultured in DMEM
medium (Invitrogen) supplemented with 10% fetal bovine
serum (FBS) (Invitrogen), 100 U/ml Penicillin, 100 μg/ml
Streptomycin and1% L-glutamine.Murinemammary carcinoma
4T1 cells were cultured in RPMI-1640 medium (Invitrogen)
supplemented with 10% FBS, 100 IU/ml Penicillin, 100 μg/ml
Streptomycin and 1% L-glutamine. Human colorectal cancer
HCT116 cells were cultured in McCoy's medium (Lonza)
supplemented with 10% FBS, 100 U/ml Penicillin, 100 μg/ml
Streptomycin and 1% L-glutamine.
Human MSCs were from Lonza and cultured in low glucose
DMEM, 10% FBS and 100 U/ml penicillin and 100 μg/ml
streptomycin.Isolation and expansion of murine MSCs
Inbred FVB/N mice, 4–6 weeks old, were sacrificed using
CO2 and their tibias and femurs were dissected and cleaned
of all soft tissue. The epiphysis of each bone was clipped,
and the bone marrow was flushed out by inserting a syringe
needle (20-gauge) into the end of the bone, and suspended
in cold DMEM-low glucose containing 100 U/ml penicillin and
100 μg/ml streptomycin. After centrifugation the cells were
resuspended and plated in T-75 tissue culture flasks using
DMEM-low glucose containing 100 U/ml penicillin and
100 μg/ml streptomycin and 15% FBS (Invitrogen). Flasks
were kept in a humidified incubator in an atmosphere of 5%
CO2 at 37 °C. The first medium replacement was done on day
3, and subsequent changes of the medium were performed
every 4 days. About 7–9 days after culture initiation, sev-
eral clones of fibroblast-shaped cells emerged. When they
reached 80–90% confluence, cultures werewashedwithwarm
PBS, and incubated at 37 °C in pre-warmed 0.25% trypsin and
0.53 mM EDTA for 2 min. Based on the method of Peister et al.
(Peister et al., 2004) for murine MSC isolation, only detached
cells after 2 min trypsin incubation were pooled and cultured
in T-75 flasks as passage-1 cells. The cells were subsequently
expanded in DMEM-low glucose with 100 U/ml penicillin and
100 μg/ml streptomycin and 15% FBS. We used cells from
passages 3–5 for our experiments.
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plated at 2×105 cells/well in a 6-well plate and incubated in
DMEM-low glucose supplemented with 15% FBS until conflu-
ence was achieved. The medium was then replaced with an
osteogenic induction medium (Iscoves supplemented with
50 μM ascorbic acid 2-phosphate, 100 nM dexamethasone and
20 mM β-glycerol phosphate, 50 ng/ml L-thyroxine, 9% FBS, 9%
equine serum, 2 mM L-glutamine 100 U/ml penicillin and
100 μg/ml streptomycin). In addition, some plates were
incubated with complete medium (Iscoves, 9% FBS, 9% equine
serum, 2 mM L-glutamine 100 U/ml penicillin and 100 μg/ml
streptomycin) to be used as controls. Medium was changed
every 2 days over a total of 21 days. Cells were then fixed with
10% formalin for 10 min and Von-Kossa staining was carried out
as follows: after being rinsed with water, cells were covered
with 3% silver nitrate solution for 10 min in the absence of light.
Cells were then rinsed and the plate was exposed to bright
warm light for 15 min. After rinsing with water images were
taken.
Chondrogenesis differentiation was performed by pellet-
ing approximately 200,000 cells by centrifugation at 300×g
for 4 min, followed by incubation at 37 °C in 5% CO2 in 1 ml
chondrogenic medium, composed of DMEM-high glucose, 1%
FBS, 50 μg/ml ascorbic acid 2-phosphate, 100 nM dexame-
tasone, 40 μg/ml L-proline, 1 mM sodium pyruvate, 10 ng/ml
TGF-β, 100 ng/ml BMP-2, ITS+supplement (final concentration:
6.25 μg/ml bovine insulin, 6.25 μg/ml transferrin, 6.25 μg/ml
selenous acid, 5.33 μg/ml linoleic acid, 1.25 mg/ml BSA) and
100 U/mlpenicillin and100 μg/ml streptomycin. After 24 hcells
begun to contract and to form a disk-like structure. Mediumwas
changed three times aweekby aspirating off asmuchmediumas
possible without disrupting the pellet and replacing it with
0.5 ml of fresh chondrogenic medium. After 21 days in culture
the pellets were harvested by aspirating off all medium and
washing twice in PBS. Pellets were then fixed for 1 h in 10%
formalin at room temperature, and paraffin embedded.
Toluidine blue staining was carried out by incubation of
deparaffinized and rehydrated sections of pellets in 0.5%
toluidine blue solution (pH 2.5) at room temperature. Slides
where then washed in deionized water, dehydrated and
mounted.
For adipogenesis, cells were plated at 2×105 cells/well, in a
6-well plate and incubated in DMEM-low glucose supplemented
with 15% FBS until full confluence was achieved. Then medium
was replacedwith differentiation medium consisting of DMEM-
high glucose, supplemented with 15% FBS, 1 mM dexametha-
sone, 1 mg/ml insulin, 100 mM indomethacin, 500 mM MIX
(3-isobutyl-1-methyl-xanthine), 100 U/ml penicillin and
100 μg/ml streptomycin. Cells were incubated at 37 °C and
5% CO2 for 72 h. Control cells received normal growthmedium.
After 72 h, the medium on differentiation-induced cells was
replaced with maintenance medium consisting of DMEM-high
glucose, supplemented with 15% FBS, 100 U/ml penicillin and
100 μg/ml streptomycin and the cells grown for another
2 days. Three cycles of induction and maintenance media
changeswere completedbefore cellswere left inmaintenance
medium for a total of 5–7 days. At the end of this period, the
cells were fixed for 10 min in 10% formalin and stained with
0.5% Oil Red O solution. After a 5 min incubation step at roomtemperature, excess dye solution was removed by washing
with 60% isopropanol, and counterstainingwas carriedoutwith
Harris-Hematoxylin 1:5 solution in water.CM-Dil labelling of MSCs
MSCs were loaded with 4 μg/ml Chloromethyl-dialkyl-
carbocyanine (CM-Dil) (Invitrogen) in pre-warmed PBS for
15 min at 37 °C followed by an incubation for 15 min at 4 °C.
The cells were washed with PBS, resuspended in their normal
growth medium and cultured for 16 h before they were used.Immuno-fluorescence studies
Four μm-paraffin tissue sections were deparaffinized and
rehydrated. Then samples were washed in PBS and antigen
unmasking was carried out in 0.01 M citric acid pH 6 using a
microwave for 10 min. Samples were cooled down to room
temperature, washed and blocked for 1 h at room temper-
ature. After the mouse anti-human CD326 (Novus Biologicals)
incubation at 4 °C overnight, the sections were washed
and the fluorophore sheep anti-mouse Dylight 488 (Jackson
Immunoresearch) was used as secondary antibody. After the
secondary antibody incubation, slides were washed in PBS,
incubated for 10 min in DAPI and mounted in fluoromount
solution.
For quantification of MSC bio-distribution, 4 μm paraffin
sections were deparaffinized and rehydrated, washed in PBS,
followed by an incubation for 10 min with DAPI, and mounted
in fluoromount solution for the detection of fluorescent
cells under a microscope. 15 randomly chosen fields/organ of
each animal were counted.Animal studies
Ten week old female CD1 nu/nu mice (Charles River) were
subcutaneously injected with 5×106 tumor cells (MDA-MB-231
or HCT116) in 200 μl PBS under the lateral skin of the right leg.
Ten week old female BALB/c mice (Charles River) were sub-
cutaneously injected with 5×106 4T1 tumor cells in 200 μl PBS
under the lateral skin of the right leg. When tumors were
palpable, the animals were injected intravenously with 1×105
CM-Dil labeled MSCs.
For the analysis of the tissue distribution of the MSCs and
their effects on metastasis formation inguinal, axillary,
mesentheric andparaaortic lymphnodes, liver, spleen, kidney,
and lung were fixed in 10% formalin. In addition, tibia and
femur, and vertebra of each animal were formalin fixed, fol-
lowed by decalcification with a solution of 8% formic acid/8%
HCl prior to tissue processing and paraffin embedding.
The animal studies were performed according to national
laws and covered by license from the Irish government.Histopathology
Organ specimens were fixed in 10% neutral buffered formalin,
and 4 μm-paraffin sections were stained with hematoxylin and
eosin (H&E) and examined using light microscopy.
171Both human and mouse mesenchymal stem cells promote breast cancer metastasisStatistical and quantitative analyses
Experimental values are always expressed as mean value±
standard error. For significance analysis ANOVA was used. The
exact p-values for the bio-distribution analyses are provided in
the supplementary material section (Supplementary Tables).
We considered pb0.05 as significant (*) and pb0.01 as highly
significant (**).
First, we counted the number of Dil-labeled MSCs in bone
marrow, spleen, liver, lymph nodes, and tumor and expressed
the numbers found in each of the tissues as percentage of
the total Dil-labeled MSCs that we counted. Hence, the figures
express the relative distribution of MSCs in these tissues. Ad-
ditionally, we have counted the total number of non-labeled
cells in the sections and expressed the number of MSCs as
percentage of total cells. This provides a measure for the
cellular density of MSCs in the respective organs.
Supplementary materials related to this article can be
found online at doi:10.1016/j.scr.2011.05.002.
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